Janssen Search
Search results
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
Mar 15, 2024 United States FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI® based on results from the Phase 3 CARTITUDE-4 study RARITAN, N.J., March 15, 2024 – Johnson & Johnson announced today that the U.S. ...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
Jun 03, 2024 New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing 1 Separate analyses from the MajesTEC-1 and OPTec studies are the first to underscore the ...
Transparency and Collaboration
Transparency and Collaboration At Janssen, we believe transparency helps to advance science and medicine; it’s in the best interests of both the people who use our pharmaceutical products and providers who prescribe them. The people and healthcare ...
How Janssen and UCSD are Joining Forces to fight Chagas disease
How Janssen and UC San Diego Are Joining Forces to Fight Chagas Disease Dean James McKerrow (UC San Diego) and Paul Jackson (Janssen) discuss the partnership. Cells before treatment showing the presence of T. Cruzi (small dots). The UC San Diego team, ...
Patient Involvement- The Sooner, The Better, says Janssen's Wooding
Article Type: Explore Patient Involvement- The Sooner, The Better, says Janssen's Wooding by Belen Diego at Eyeforpharma Barcelona BARCELONA, March 17, 2017 (APM)- Janssen's head of global commercial strategy organisation supports moves to ...
An Inspiring Weekend with Inspiring People at HealtheVoices
An Inspiring Weekend With Inspiring People at HealtheVoices I had the honor of attending the annual HealtheVoices Conference in Chicago, Illinois, during the weekend of April 21. Now in its third year, this conference is organized by Janssen and brings ...
Strengthening Our Resolve to Eliminate Cancer
ASCO: The Annual Meeting that Strengthens Our Resolve to Eliminate Cancer Every year, I look forward to attending the ASCO Annual Meeting that brings together over 40,000 in the field of oncology. I cannot help but be inspired by the many people who ...
Working Together Toward Patient-Inspired Innovation
Working Together Toward Patient-Inspired Innovation We have redefined our existing relationship with patients by creating a Patient Engagement model where we engage with patients early, systematically, and directly on the most important aspects of drug ...
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
Apr 08, 2024 United States New exploratory analysis demonstrates consistent results of XARELTO ® in treating elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention XARELTO ® is one of the most ...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Jun 20, 2024 TREMFYA® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. (June 20, 2024) /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 ...